O	0	10	Randomized
O	11	16	trial
O	17	26	comparing
B-intervention	27	35	axillary
I-intervention	36	45	clearance
O	46	52	versus
B-control	53	55	no
I-control	56	64	axillary
I-control	65	74	clearance
O	75	77	in
O	78	83	older
O	84	92	patients
O	93	97	with
O	98	104	breast
O	105	111	cancer
O	111	112	:
O	113	118	first
O	119	126	results
O	127	129	of
O	130	143	International
O	144	150	Breast
O	151	157	Cancer
O	158	163	Study
O	164	169	Group
O	170	175	Trial
O	176	178	10
O	178	179	-
O	179	181	93
O	181	182	.

O	183	191	Axillary
O	192	201	clearance
O	202	204	in
O	205	210	early
O	211	217	breast
O	218	224	cancer
O	225	229	aims
O	230	232	to
O	233	240	improve
O	241	253	locoregional
O	254	261	control
O	262	265	and
O	266	273	provide
O	274	281	staging
O	282	293	information
O	294	297	but
O	298	300	is
O	301	311	associated
O	312	316	with
O	317	328	undesirable
O	329	338	morbidity
O	338	339	.

O	340	342	We
O	343	352	therefore
O	353	365	investigated
O	366	373	whether
O	374	382	avoiding
O	383	391	axillary
O	392	399	surgery
O	400	402	in
O	403	408	older
O	409	414	women
O	415	420	would
O	421	427	result
O	428	430	in
O	431	439	improved
O	440	447	quality
O	448	450	of
O	451	455	life
O	456	457	(
O	457	459	QL
O	459	460	)
O	461	465	with
O	466	473	similar
O	474	481	disease
O	481	482	-
O	482	486	free
O	487	495	survival
O	496	497	(
O	497	500	DFS
O	500	501	)
O	502	505	and
O	506	513	overall
O	514	522	survival
O	523	524	(
O	524	526	OS
O	526	527	)
O	527	528	.

O	529	536	Between
O	537	541	1993
O	542	545	and
O	546	550	2002
O	550	551	,
O	552	557	women
O	558	559	>
O	560	562	or
O	563	564	=
O	565	567	60
O	568	573	years
O	574	577	old
B-eligibility	578	582	with
I-eligibility	583	593	clinically
I-eligibility	594	598	node
I-eligibility	598	599	-
I-eligibility	599	607	negative
I-eligibility	608	616	operable
I-eligibility	617	623	breast
I-eligibility	624	630	cancer
I-eligibility	631	633	in
I-eligibility	634	638	whom
I-eligibility	639	647	adjuvant
I-eligibility	648	657	tamoxifen
I-eligibility	658	661	was
I-eligibility	662	672	considered
I-eligibility	673	682	indicated
I-eligibility	683	693	regardless
I-eligibility	694	696	of
I-eligibility	697	707	pathologic
I-eligibility	708	713	nodal
I-eligibility	714	720	status
O	721	725	were
O	726	734	randomly
O	735	743	assigned
O	744	746	to
O	747	754	primary
O	755	762	surgery
O	763	767	plus
O	768	776	axillary
O	777	786	clearance
O	787	788	(
O	788	790	Sx
O	791	792	+
O	793	795	Ax
O	795	796	)
O	797	805	followed
O	806	808	by
O	809	818	tamoxifen
O	819	820	(
O	820	823	Tam
O	823	824	)
O	825	831	versus
O	832	834	Sx
O	835	842	without
O	843	845	Ax
O	846	854	followed
O	855	857	by
O	858	861	Tam
O	862	865	for
O	866	867	5
O	868	879	consecutive
O	880	885	years
O	885	886	.

O	887	890	The
O	891	898	primary
O	899	902	end
O	903	908	point
O	909	912	was
B-outcome-Measure	913	915	QL
O	916	924	reported
O	925	927	by
O	928	931	the
O	932	939	patient
O	940	943	and
O	944	946	by
O	947	956	physician
O	957	967	assessment
O	967	968	.

O	969	970	A
O	971	976	total
O	977	979	of
B-total-participants	980	983	473
O	984	992	patients
O	993	994	(
B-intervention-participants	994	997	234
O	998	1000	to
O	1001	1003	Sx
O	1004	1005	+
O	1006	1008	Ax
O	1008	1009	,
B-control-participants	1010	1013	239
O	1014	1016	to
O	1017	1019	Sx
O	1019	1020	)
O	1021	1025	were
O	1026	1034	randomly
O	1035	1043	assigned
O	1043	1044	.

O	1045	1048	The
O	1049	1055	median
O	1056	1059	age
O	1060	1063	was
B-age	1064	1066	74
I-age	1067	1072	years
O	1072	1073	;
O	1074	1076	80
O	1076	1077	%
O	1078	1081	had
O	1082	1090	estrogen
O	1091	1099	receptor
O	1099	1100	-
O	1100	1108	positive
O	1109	1116	disease
O	1116	1117	.

O	1118	1120	In
O	1121	1125	both
O	1126	1129	the
O	1130	1138	patients
O	1138	1139	'
O	1140	1150	subjective
O	1151	1161	assessment
O	1162	1164	of
O	1165	1170	their
O	1171	1173	QL
O	1174	1177	and
O	1178	1181	the
O	1182	1192	physicians
O	1192	1193	'
O	1194	1204	perception
O	1205	1207	of
O	1208	1211	the
O	1212	1220	patients
O	1220	1221	'
O	1222	1224	QL
O	1224	1225	,
O	1226	1229	the
O	1230	1237	largest
O	1238	1245	adverse
O	1246	1248	QL
O	1249	1256	effects
O	1257	1259	of
O	1260	1262	Ax
O	1263	1267	were
O	1268	1276	observed
O	1277	1281	from
O	1282	1290	baseline
O	1291	1293	to
O	1294	1297	the
O	1298	1303	first
O	1304	1317	postoperative
O	1318	1328	assessment
O	1328	1329	,
O	1330	1333	but
O	1334	1337	the
O	1338	1349	differences
O	1350	1356	tended
O	1357	1359	to
O	1360	1369	disappear
O	1370	1372	in
O	1373	1374	6
O	1375	1377	to
O	1378	1380	12
O	1381	1387	months
O	1387	1388	.

O	1389	1391	At
O	1392	1393	a
O	1394	1400	median
O	1401	1407	follow
O	1407	1408	-
O	1408	1410	up
O	1411	1413	of
O	1414	1415	6
O	1415	1416	.
O	1416	1417	6
O	1418	1423	years
O	1423	1424	,
O	1425	1432	results
O	1433	1436	for
O	1437	1439	Sx
O	1440	1441	+
O	1442	1444	Ax
O	1445	1448	and
O	1449	1451	Sx
O	1452	1459	yielded
O	1460	1467	similar
B-outcome	1468	1471	DFS
O	1472	1473	(
B-outcome	1473	1474	6
I-outcome	1474	1475	-
I-outcome	1475	1479	year
I-outcome	1480	1483	DFS
O	1483	1484	,
B-iv-bin-percent	1485	1487	67
I-iv-bin-percent	1487	1488	%
O	1489	1490	v
B-cv-bin-percent	1491	1493	66
I-cv-bin-percent	1493	1494	%
O	1494	1495	;
O	1496	1502	hazard
O	1503	1508	ratio
O	1509	1510	[
O	1510	1512	HR
O	1512	1513	]
O	1514	1516	Sx
O	1517	1518	+
O	1519	1521	Ax
O	1521	1522	/
O	1522	1524	Sx
O	1524	1525	,
O	1526	1527	1
O	1527	1528	.
O	1528	1530	06
O	1530	1531	;
O	1532	1534	95
O	1534	1535	%
O	1536	1538	CI
O	1538	1539	,
O	1540	1541	0
O	1541	1542	.
O	1542	1544	79
O	1545	1547	to
O	1548	1549	1
O	1549	1550	.
O	1550	1552	42
O	1552	1553	;
O	1554	1555	P
O	1556	1557	=
O	1558	1559	.
O	1559	1561	69
O	1561	1562	)
O	1563	1566	and
B-outcome	1567	1569	OS
O	1570	1571	(
B-outcome	1571	1572	6
I-outcome	1572	1573	-
I-outcome	1573	1577	year
I-outcome	1578	1580	OS
O	1580	1581	,
B-iv-bin-percent	1582	1584	75
I-iv-bin-percent	1584	1585	%
O	1586	1587	v
B-cv-bin-percent	1588	1590	73
I-cv-bin-percent	1590	1591	%
O	1591	1592	;
O	1593	1595	HR
O	1596	1598	Sx
O	1599	1600	+
O	1601	1603	Ax
O	1603	1604	/
O	1604	1606	Sx
O	1606	1607	,
O	1608	1609	1
O	1609	1610	.
O	1610	1612	05
O	1612	1613	;
O	1614	1616	95
O	1616	1617	%
O	1618	1620	CI
O	1620	1621	,
O	1622	1623	0
O	1623	1624	.
O	1624	1626	76
O	1627	1629	to
O	1630	1631	1
O	1631	1632	.
O	1632	1634	46
O	1634	1635	;
O	1636	1637	P
O	1638	1639	=
O	1640	1641	.
O	1641	1643	77
O	1643	1644	)
O	1644	1645	.

O	1646	1654	Avoiding
O	1655	1663	axillary
O	1664	1673	clearance
O	1674	1677	for
O	1678	1683	women
O	1684	1685	>
O	1686	1688	or
O	1689	1690	=
O	1691	1693	60
O	1694	1699	years
O	1700	1703	old
O	1704	1707	who
O	1708	1712	have
O	1713	1723	clinically
O	1724	1728	node
O	1728	1729	-
O	1729	1737	negative
O	1738	1745	disease
O	1746	1749	and
O	1750	1757	receive
O	1758	1761	Tam
O	1762	1765	for
O	1766	1775	endocrine
O	1775	1776	-
O	1776	1786	responsive
O	1787	1794	disease
O	1795	1801	yields
O	1802	1809	similar
O	1810	1818	efficacy
O	1819	1823	with
O	1824	1830	better
O	1831	1836	early
O	1837	1839	QL
O	1839	1840	.
